1. Home
  2. MDGL vs HIMS Comparison

MDGL vs HIMS Comparison

Compare MDGL & HIMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDGL
  • HIMS
  • Stock Information
  • Founded
  • MDGL 2011
  • HIMS 2017
  • Country
  • MDGL United States
  • HIMS United States
  • Employees
  • MDGL N/A
  • HIMS N/A
  • Industry
  • MDGL Biotechnology: Pharmaceutical Preparations
  • HIMS Medical/Nursing Services
  • Sector
  • MDGL Health Care
  • HIMS Health Care
  • Exchange
  • MDGL Nasdaq
  • HIMS Nasdaq
  • Market Cap
  • MDGL 9.6B
  • HIMS 12.2B
  • IPO Year
  • MDGL N/A
  • HIMS N/A
  • Fundamental
  • Price
  • MDGL $418.91
  • HIMS $47.26
  • Analyst Decision
  • MDGL Strong Buy
  • HIMS Hold
  • Analyst Count
  • MDGL 12
  • HIMS 12
  • Target Price
  • MDGL $521.09
  • HIMS $37.20
  • AVG Volume (30 Days)
  • MDGL 273.4K
  • HIMS 31.2M
  • Earning Date
  • MDGL 11-04-2025
  • HIMS 11-03-2025
  • Dividend Yield
  • MDGL N/A
  • HIMS N/A
  • EPS Growth
  • MDGL N/A
  • HIMS 866.21
  • EPS
  • MDGL N/A
  • HIMS 0.79
  • Revenue
  • MDGL $515,547,000.00
  • HIMS $2,013,538,000.00
  • Revenue This Year
  • MDGL $394.38
  • HIMS $61.66
  • Revenue Next Year
  • MDGL $64.73
  • HIMS $19.48
  • P/E Ratio
  • MDGL N/A
  • HIMS $60.17
  • Revenue Growth
  • MDGL 3421.98
  • HIMS 88.69
  • 52 Week Low
  • MDGL $200.63
  • HIMS $18.33
  • 52 Week High
  • MDGL $463.63
  • HIMS $72.98
  • Technical
  • Relative Strength Index (RSI)
  • MDGL 43.46
  • HIMS 40.30
  • Support Level
  • MDGL $418.88
  • HIMS $49.73
  • Resistance Level
  • MDGL $445.06
  • HIMS $65.30
  • Average True Range (ATR)
  • MDGL 16.62
  • HIMS 4.44
  • MACD
  • MDGL -3.45
  • HIMS -1.25
  • Stochastic Oscillator
  • MDGL 12.79
  • HIMS 5.80

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

About HIMS Hims & Hers Health Inc.

Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.

Share on Social Networks: